New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban

Area of Science:

• Cardiology
• Pharmacology
• Clinical Practice

Background:

• Atrial fibrillation (AF) combined with coronary artery disease (CAD) presents a common yet complex clinical scenario.
• This combination is associated with significantly higher mortality rates.
• Optimal anticoagulation and antiplatelet strategies remain challenging due to insufficient clinical data.

Purpose of the Study:

• To review the use of newer oral anticoagulants (NOACs) in combination with dual antiplatelet therapy (DAPT).
• Focus on patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).
• Address the clinical uncertainty surrounding antithrombotic combinations in patients with both AF and CAD.

Main Methods:

• Review of existing literature on NOACs and DAPT in patients with AF and CAD undergoing PCI.
• Analysis of the lack of randomized controlled trials comparing different antithrombotic strategies.
• Examination of newer antiplatelet agents (e.g., ticagrelor, prasugrel) in this patient population.

Main Results:

• No randomized studies directly compare vitamin K antagonists (VKAs) with NOACs in AF patients undergoing PCI.
• Limited large-scale randomized studies evaluate newer antiplatelet agents with VKAs or NOACs in AF patients with CAD.
• Significant uncertainty exists regarding optimal antithrombotic combinations for patients with concurrent AF and CAD.

Conclusions:

• The lack of robust outcome trial data leads to wide variations in clinical practice.
• A watchful approach is recommended when using NOACs as part of DAPT or triple oral antithrombotic therapy.
• Further research is crucial to establish evidence-based guidelines for managing these complex patients.